[What are the special features of the treatment of venous thromboembolic disease in the course of cancer?]
Rev Mal Respir
.
2021 Apr:38 Suppl 1:e138-e144.
doi: 10.1016/j.rmr.2019.05.011.
Epub 2019 Nov 6.
[Article in French]
Authors
I Mahé
1
,
G Meyer
2
,
O Sanchez
3
;
groupe de travail Recommandations de bonne pratique pour la prise en charge de la MVTE
Affiliations
1
F-CRIN INNOVTE, 42055 Saint-Étienne cedex 2, France; Université de Paris, Service de médecine interne, AH-HP, hôpital Louis-Mourier, 92700 Colombes, France; Innovations Thérapeutiques en Hémostase, INSERM UMRS 1140, 75006 Paris, France.
2
F-CRIN INNOVTE, 42055 Saint-Étienne cedex 2, France; Université de Paris, Service de pneumologie et soins intensifs, AH-HP, Hôpital Européen Georges-Pompidou, 75015 Paris, France; INSERM UMRS 970, INSERM CIC 1418, 75015 Paris, France.
3
F-CRIN INNOVTE, 42055 Saint-Étienne cedex 2, France; Innovations Thérapeutiques en Hémostase, INSERM UMRS 1140, 75006 Paris, France; Université de Paris, Service de pneumologie et soins intensifs, AH-HP, Hôpital Européen Georges-Pompidou, 75015 Paris, France. Electronic address:
[email protected]
.
PMID:
31703829
DOI:
10.1016/j.rmr.2019.05.011
No abstract available
Publication types
Practice Guideline
MeSH terms
Humans
Neoplasms* / complications
Neoplasms* / therapy
Risk Factors
Thromboembolism*
Venous Thromboembolism* / diagnosis
Venous Thromboembolism* / epidemiology
Venous Thromboembolism* / etiology
Venous Thrombosis*